{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T10:40:45Z","timestamp":1793356845762,"version":"4.5.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004897","name":"European Organisation for Research and Treatment of Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.ctro.2026.101296","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:12:08Z","timestamp":1790349128000},"page":"101296","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The value of community engagement in the ESTRO\u2013EORTC OligoCare project: A quantification of the in-kind contributions"],"prefix":"10.1016","volume":"62","author":[{"given":"Davide","family":"Cusumano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Scaggion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolande","family":"Lievens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Clementel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Nuyens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Alongi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergi","family":"Benavente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e8tra","family":"Braam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet","family":"Dirix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Hemmatazad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Jeene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara Alicja","family":"Jereczek-Fossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Greto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ramella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasna","family":"But-Hadzic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Ricardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Salinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Scorsetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Sirak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Stellamans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Widder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet","family":"Ost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Guckenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctro.2026.101296_bb0005","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJMra1608986","article-title":"Recent developments in radiotherapy","volume":"377","author":"Citrin","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctro.2026.101296_bb0010","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/S1470-2045(22)00752-5","article-title":"Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium","volume":"24","author":"Kroeze","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctro.2026.101296_bb0015","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/1878-0261.12731","article-title":"What will radiation oncology look like in 2050? A look at a changing professional landscape in Europe and beyond","volume":"14","author":"Baumann","year":"2020","journal-title":"Mol Oncol"},{"key":"10.1016\/j.ctro.2026.101296_bb0020","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1016\/S1470-2045(25)00732-6","article-title":"An international modified Delphi study to prioritise levels of evidence and outcomes to appraise radiotherapy innovation in the ESTRO value-based radiation oncology framework","volume":"27","author":"Vandemaele","year":"2026","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctro.2026.101296_bb0025","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.1016\/S1470-2045(26)00075-6","article-title":"Clinical trial endpoints for metastases-directed therapy in oligometastatic cancer: a review and Delphi consensus on behalf of the EORTC\u2013ESTRO OligoCare consortium","volume":"27","author":"Widder","year":"2026","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctro.2026.101296_bb0030","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1056\/NEJMms1604593","article-title":"Assessing the gold standard--lessons from the history of RCTs","volume":"374","author":"Bothwell","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctro.2026.101296_bb0035","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1016\/S1470-2045(18)30917-3","article-title":"Towards an evidence-informed value scale for surgical and radiation oncology: a multi-stakeholder perspective","volume":"20","author":"Lievens","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctro.2026.101296_bb0040","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-world evidence - what is it and what can it tell us?","volume":"375","author":"Sherman","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctro.2026.101296_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110235","article-title":"Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: an interim analysis of the EORTC-ESTRO E2-RADIatE OligoCare study","volume":"195","author":"Christ","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2026.101296_bb0050","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European organisation for research and treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctro.2026.101296_bb0055","article-title":"Health-related quality of life in men with oligometastatic prostate cancer following metastases-directed stereotactic body radiotherapy: real-world data from the E2-RADIatE OligoCare cohort","volume":"45","author":"Bultijnck","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ctro.2026.101296_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110466","article-title":"Acute toxicity in patients with oligometastatic cancer following metastasis-directed stereotactic body radiotherapy: an interim analysis of the E2-RADIatE OligoCare cohort","volume":"199","author":"Alongi","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2026.101296_bb0065","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.radonc.2017.08.021","article-title":"Cost evaluation to optimise radiation therapy implementation in different income settings: a time-driven activity-based analysis","volume":"125","author":"Dyk","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2026.101296_bb0070","series-title":"Health statistics 2025: Remuneration of health professionals","author":"OECD","year":"2025"},{"key":"10.1016\/j.ctro.2026.101296_bb0075","unstructured":"Eurostat. Labour cost levels by NACE Rev. 2 activity (lc_lci_lev). https:\/\/ec.europa.eu\/eurostat (accessed 22 August 2025)."},{"key":"10.1016\/j.ctro.2026.101296_bb0080","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/S1470-2045(22)00540-X","article-title":"European Groundshot-addressing Europe\u2019s cancer research challenges: a lancet oncology commission","volume":"24","author":"Lawler","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctro.2026.101296_bb0085","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1470-2045(23)00182-1","article-title":"Global funding for cancer research between 2016 and 2020: a content analysis of public and philanthropic investments","volume":"24","author":"McIntosh","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctro.2026.101296_bb0090","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.15445","article-title":"Costs of drug development and Research and Development intensity in the US, 2000-2018","volume":"7","author":"Sertkaya","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ctro.2026.101296_bb0095","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.radonc.2014.08.034","article-title":"Radiotherapy staffing in the European countries: final results from the ESTRO-HERO survey","volume":"112","author":"Lievens","year":"2014","journal-title":"Radiother Oncol"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630826001916?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630826001916?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T10:06:51Z","timestamp":1793354811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630826001916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":19,"alternative-id":["S2405630826001916"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101296","relation":{},"ISSN":["2405-6308"],"issn-type":[{"value":"2405-6308","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The value of community engagement in the ESTRO\u2013EORTC OligoCare project: A quantification of the in-kind contributions","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101296","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101296"}}